Join Dr Flora Mansour (NIF Radiochemistry Manager) and Dr Yasser Hadi Gholami (NIF Preclinical Imaging Fellow) as they moderate an expert panel discussion exploring the future of Targeted Alpha Therapy (TAT) and its potential to transform patient care in Australia.

Australia is at a pivotal point in the development of Targeted Alpha Therapy (TAT), with growing research, clinical interest, and investment creating significant opportunities to improve patient outcomes. This expert panel will bring together leaders from nuclear medicine, radiopharmacy, radiochemistry, manufacturing, regulation, and clinical translation to explore the practical steps needed to make TAT more accessible to Australian patients. Through a forward-looking discussion, panelists will examine challenges such as radionuclide supply, manufacturing capability, regulatory pathways, workforce development, and clinical trial infrastructure, while highlighting the opportunities that could position Australia as a leader in this rapidly emerging field. Attendees will gain valuable insights into the current landscape and the collaborative efforts required to bring TAT from research and clinical trials into routine clinical practice.

Contact the host of Panel Discussion: Translating Targeted Alpha Therapy for the Benefit of Australian Patients

There were 0 errors found in the information you submitted: